Helix Biopharma Corp Stock Market Value
| HBPCF Stock | USD 1.73 0.00 0.00% |
| Symbol | Helix |
Helix BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Helix BioPharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Helix BioPharma.
| 12/31/2024 |
| 12/26/2025 |
If you would invest 0.00 in Helix BioPharma on December 31, 2024 and sell it all today you would earn a total of 0.00 from holding Helix BioPharma Corp or generate 0.0% return on investment in Helix BioPharma over 360 days. Helix BioPharma is related to or competes with Relief Therapeutics, Calliditas Therapeutics, Relief Therapeutics, Arch Biopartners, Zivo Bioscience, and Vicapsys Life. Helix BioPharma Corp. operates as an immune-oncology company in Canada More
Helix BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Helix BioPharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Helix BioPharma Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1226 | |||
| Maximum Drawdown | 188.33 |
Helix BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Helix BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Helix BioPharma's standard deviation. In reality, there are many statistical measures that can use Helix BioPharma historical prices to predict the future Helix BioPharma's volatility.| Risk Adjusted Performance | 0.0984 | |||
| Jensen Alpha | 3.23 | |||
| Total Risk Alpha | 0.6106 | |||
| Treynor Ratio | (0.85) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Helix BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Helix BioPharma Corp Backtested Returns
Helix BioPharma is out of control given 3 months investment horizon. Helix BioPharma Corp holds Efficiency (Sharpe) Ratio of 0.13, which attests that the entity had a 0.13 % return per unit of risk over the last 3 months. We were able to break down sixteen different technical indicators, which can help you to evaluate if expected returns of 2.99% are justified by taking the suggested risk. Use Helix BioPharma Corp Market Risk Adjusted Performance of (0.84), standard deviation of 23.73, and Risk Adjusted Performance of 0.0984 to evaluate company specific risk that cannot be diversified away. Helix BioPharma holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -3.52, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Helix BioPharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Helix BioPharma is expected to outperform it. Use Helix BioPharma Corp variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to analyze future returns on Helix BioPharma Corp.
Auto-correlation | 0.00 |
No correlation between past and present
Helix BioPharma Corp has no correlation between past and present. Overlapping area represents the amount of predictability between Helix BioPharma time series from 31st of December 2024 to 29th of June 2025 and 29th of June 2025 to 26th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Helix BioPharma Corp price movement. The serial correlation of 0.0 indicates that just 0.0% of current Helix BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Helix BioPharma Corp lagged returns against current returns
Autocorrelation, which is Helix BioPharma pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Helix BioPharma's pink sheet expected returns. We can calculate the autocorrelation of Helix BioPharma returns to help us make a trade decision. For example, suppose you find that Helix BioPharma has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Helix BioPharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Helix BioPharma pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Helix BioPharma pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Helix BioPharma pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Helix BioPharma Lagged Returns
When evaluating Helix BioPharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Helix BioPharma pink sheet have on its future price. Helix BioPharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Helix BioPharma autocorrelation shows the relationship between Helix BioPharma pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Helix BioPharma Corp.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Helix Pink Sheet
Helix BioPharma financial ratios help investors to determine whether Helix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.